Princeton, NJ, United States

Bristol Myers Squibb

www.bms.com
Princeton, NJ, United States

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."BMS' primary R&D sites are located in Lawrence Township and Wallingford, Connecticut , with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, and Bangalore, India. Wikipedia.


Time filter

Source Type

Patent
Bristol Myers Squibb | Date: 2017-03-22

The application provides Fc fusion proteins having novel arrangements. In particular, the application provides Fc fusion proteins comprising a ^(10)Fn3 domain and a linker derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.


Patent
Bristol Myers Squibb | Date: 2017-02-01

A compound of formula I_(1) and R_(24) are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I_(Kur)-associated disorders, and other disorders mediated by ion channel function.


Patent
Bristol Myers Squibb | Date: 2017-01-11

A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.


Patent
Bristol Myers Squibb | Date: 2017-05-03

The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.


Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV : formula (I).


The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.


Patent
Bristol Myers Squibb | Date: 2017-01-25

Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I)


Patent
Bristol Myers Squibb | Date: 2017-08-09

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.


Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.


Patent
Bristol Myers Squibb | Date: 2017-07-19

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Loading Bristol Myers Squibb collaborators
Loading Bristol Myers Squibb collaborators